IceCure Medical Ltd. (ICCM) company profile
Close on Nov 17, 2026Market cap $2.84MP/E 0.1Yield –
About IceCure Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
IceCure Medical Ltd. is an Israeli medical device company that researches, develops, and commercializes liquid-nitrogen-based cryoablation systems to destroy benign and malignant tumors through freezing. Its proprietary technology provides a minimally invasive alternative to surgery for tumors in the breast, lungs, kidneys, and bones. The company's lead commercial product is the ProSense system alongside its single-use disposable CryoProbes, while its pipeline includes next-generation systems such as the single-probe XSense and multi-probe MSense platforms. IceCure primarily markets its cryoablation products to healthcare providers, physicians, and hospitals treating low-risk breast cancer and other tumor indications.
The company's cryoablation systems hold regulatory approvals for various clinical indications in 27 countries, including the United States, several European nations, China, India, and Brazil. IceCure maintains its corporate headquarters and principal executive offices in Caesarea, Israel, and operates wholly owned subsidiaries in the United States and Hong Kong.
Summary of the business section of IceCure Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IceCure Medical Ltd.
- Founded
- 2006
- Headquarters
- Caesarea, Israel
- Address
- 7 Ha'Eshel St., Pob 3163 38900
- Phone
- 972-4-6230333
- Website
- icecure-medical.com
- Employees
- 67, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- ICCM
- Exchange
- Nasdaq
- IPO date
- Aug 26, 2021
- Shares outstanding
- 73M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Jun 4, 2026
- SEC CIK
- 1584371
- CUSIP
- M53071136
- FIGI
- BBG005K17W05
- Share class FIGI
- BBG001V04FF8
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eyal Shamir | Chief Executive Officer, Director | 431,281 |
| Shad Good | VP, Sales for North America | 136,698 |
| Shay Levav | Chief Operating Officer | 146,303 |
| Tlalit Bussi Tel-Tzure | VP, BD & Global Marketing | 106,518 |
| Meir Peleg | Chief Financial Officer | 194,816 |
| Merav Nir Dotan | VP, Human Resources | 76,168 |
| Naum Muchnik | VP, R&D & Engineering | 118,621 |
| Ronen Tsimerman | Chief Financial Officer | 177,949 |
| Ron Mayron | Director | 176,464 |
| David Salton | Director | – |
| Vincent Chun Hung Chan | Director | – |
| Sharon Levita | Director | – |
| Yonatan Malca | Director | – |
| Yang Huang | Director | 111,468 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 10, 2021
- Offer price
- $3.45
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Jun 8, 2022
“Per Ordinary Share Per Pre-Funded Warrant Total Public offering price $ 3.45 $ 3.449 $ 14,998,969.15 Underwriting discounts and commissions (1) $ 0.1104 $ 0.1035 $ 472,729 Proceeds to us (before expenses) $ 3.34 $ 3.35 $ 14,526,240.15 (1) The underwriters will receive an underwriting discount equal to 7.0% of the gross proceeds in this offering (”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“we had 67 full-time employees and two part time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?